Cystoscopy, Phenazopyridine
Conditions
Brief summary
The investigators propose to conduct a randomized controlled trial to evaluate whether administration of phenazopyridine prior to the procedure decreases office cystoscopy time. Women undergoing in-office cystoscopy at Boston Urogynecology will be recruited.
Detailed description
All potentially eligible participants will have had a complete history, physical examination, urinalysis and urine culture for clinical purposes. After eligibility is confirmed and written, informed consent is obtained, participants will be randomized to one of the two study arms. Participants randomized to phenazopyridine arm will receive 200 mg by mouth approximately 60 minutes prior to the scheduled cystoscopy. During the cystoscopy, at various time points, the time will be recorded.The color of the efflux will also be documented.
Interventions
DRUGPhenazopyridine
Sponsors
Boston Urogynecology Associates
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Female patients undergoing in-office diagnostic cystoscopy at Boston Urogynecology Associates
Exclusion criteria
* Women who have taken vitamin B the day of the cystoscopy * Cystoscopy with concurrent treatments such as botulinum toxin or periurethral bulking injections * Allergy to phenazopyridine
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Total cystoscopy time | at time of cystoscopy | The total time of cystoscopy will be measured |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to visualization of ureteral jets | at time of cystoscopy | The time to visualization of the first ureteral jet will be recorded |
Countries
United States
Outcome results
None listed